[Skip to Content]
[Skip to Content Landing]
Article
November 1985

Maintenance Chemotherapy for High-Risk PatientsA Preliminary Report

Author Affiliations

From the Department of Otolaryngology, Eye and Ear Hospital of Pittsburgh (Drs Johnson, Myers, and Schramm and Mss Sigler and Wagner), and the Department of Medicine, Presbyterian-University Hospital, University of Pittsburgh School of Medicine (Drs Srodes, Mayernik, and Nolan).

Arch Otolaryngol. 1985;111(11):727-729. doi:10.1001/archotol.1985.00800130059005
Abstract

• A prospectively designed program employing surgery, radiotherapy, and maintenance chemotherapy was initiated for patients with histologic evidence of extracapsular spread of tumor in cervical metastases. Postoperative radiotherapy consisted of 6,000 rad of cobalt 60 administered in 180- to 200-rad fractions. Chemotherapy was initiated two to four weeks following radiotherapy. Methotrexate sodium (250 mg/sq m), fluorouracil (600 mg/sq m), and leucovorin calcium were administered one day per week, two weeks of three, for a total of 18 treatments in six months. Thirty-two patients have been in the therapeutic program. Toxic reaction has been minimal and selflimiting. One patient stopped chemotherapy because of toxic reaction. One patient (3%) was noncompliant. All patients have been followed up for 18 to 33 months. Twenty-one patients remain alive and free of disease (81% determinate survival). This compares with a 36% (9/25) disease-free survival for concurrent controls and 39% survival for historic controls.

(Arch Otolaryngol 1985;111:727-729)

×